Description

FERITAS INJ 10ML

Indications

FERITAS INJ 10ML is primarily indicated for the treatment of iron deficiency anemia in patients who are unable to tolerate oral iron supplements or in cases where oral therapy is ineffective. This injectable formulation is particularly beneficial for individuals with chronic kidney disease, those undergoing hemodialysis, and patients with gastrointestinal disorders that impair iron absorption. Additionally, it may be used in patients with increased iron requirements, such as pregnant women or those with heavy menstrual bleeding.

Mechanism of Action

FERITAS INJ contains ferric carboxymaltose, a complex of iron that facilitates the delivery of iron to the body. Upon administration, the ferric ions are released and can be utilized in the synthesis of hemoglobin and myoglobin, essential proteins for oxygen transport and storage in the body. The formulation helps replenish iron stores in the body, correcting the deficiency and improving erythropoiesis (the production of red blood cells). This mechanism is particularly effective in rapidly restoring iron levels compared to oral iron supplements, which may take longer to achieve therapeutic levels.

Pharmacological Properties

FERITAS INJ exhibits several pharmacological properties that make it suitable for treating iron deficiency anemia. The pharmacokinetics of ferric carboxymaltose indicate that it is rapidly absorbed and distributed in the body following intravenous administration. The half-life of the drug allows for dosing every few weeks, making it convenient for patients. Moreover, the formulation is designed to minimize the risk of adverse reactions commonly associated with iron therapy, such as gastrointestinal disturbances. The drug is primarily excreted through the reticuloendothelial system, with minimal renal clearance.

Contraindications

FERITAS INJ is contraindicated in patients with known hypersensitivity to ferric carboxymaltose or any of its components. It should not be used in patients with non-iron deficiency anemia, such as anemia of chronic disease, as it may lead to iron overload. Additionally, patients with severe liver dysfunction or those with a history of iron overload disorders, such as hemochromatosis or hemosiderosis, should avoid this treatment. Caution is advised in patients with a history of allergic reactions to intravenous iron preparations.

Side Effects

The administration of FERITAS INJ may lead to some side effects, although many patients tolerate the treatment well. Common side effects include headache, dizziness, and injection site reactions such as pain, swelling, or redness. Less frequently, patients may experience gastrointestinal symptoms, including nausea or diarrhea. Serious adverse effects, although rare, may include hypersensitivity reactions, hypotension, or anaphylaxis. It is essential for healthcare providers to monitor patients for any signs of adverse reactions during and after administration.

Dosage and Administration

FERITAS INJ is typically administered intravenously by a healthcare professional. The recommended dosage for adults is based on the patient’s weight and the severity of iron deficiency. A common regimen is 15 mg of iron per kilogram of body weight, administered as a single dose or divided into multiple doses over several weeks. For patients with chronic kidney disease, the dosage may be adjusted according to individual needs and response to therapy. It is crucial to follow the manufacturer’s guidelines and consult a healthcare provider for personalized dosing recommendations.

Interactions

FERITAS INJ may interact with certain medications, potentially affecting their efficacy or increasing the risk of adverse effects. For instance, concomitant use of other iron supplements or medications that affect iron metabolism, such as antacids, may interfere with the absorption and effectiveness of the treatment. Additionally, certain antibiotics, such as tetracyclines and fluoroquinolones, may have reduced absorption when taken with iron. It is important for patients to inform their healthcare providers about all medications they are currently taking to avoid potential interactions.

Precautions

Before administering FERITAS INJ, healthcare providers should conduct a thorough assessment of the patient’s medical history, including any previous reactions to iron therapy. Patients with a history of asthma, eczema, or other allergic conditions may be at higher risk for hypersensitivity reactions. Monitoring of iron levels and hemoglobin concentrations is recommended to ensure effective treatment and prevent iron overload. Pregnant and breastfeeding women should discuss the risks and benefits of treatment with their healthcare provider. It is also essential to ensure that patients are informed about the signs of potential side effects and when to seek medical attention.

Clinical Studies

Several clinical studies have demonstrated the efficacy and safety of FERITAS INJ in treating iron deficiency anemia. In a randomized controlled trial, patients receiving ferric carboxymaltose showed significant improvements in hemoglobin levels and iron stores compared to those receiving placebo or oral iron supplements. The rapid increase in hemoglobin levels and the favorable safety profile make this injectable formulation a preferred choice for patients with severe iron deficiency. Furthermore, long-term studies have indicated sustained efficacy with repeated doses, supporting its use in chronic conditions requiring ongoing iron supplementation.

Conclusion

FERITAS INJ 10ML is a valuable therapeutic option for the management of iron deficiency anemia, particularly in patients who are unable to tolerate oral iron or require rapid replenishment of iron stores. Its unique formulation allows for effective iron delivery with a favorable safety profile. Healthcare providers should consider individual patient needs and monitor for any potential side effects during treatment. As with any medication, responsible use and adherence to dosing guidelines are crucial for achieving optimal therapeutic outcomes.